Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …
K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA …, 2016 - jamanetwork.com
Importance Continuing molecularly targeted treatment beyond disease progression in non–
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
Drug rechallenge and treatment beyond progression—implications for drug resistance
The established dogma in oncology for managing recurrent or refractory disease dictates
that therapy is changed at disease progression, because the cancer is assumed to have …
that therapy is changed at disease progression, because the cancer is assumed to have …
[HTML][HTML] Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
Background Crizotinib is approved to treat advanced ALK-positive non-small-cell lung
cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We …
cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We …
[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
T Iuchi, M Shingyoji, M Itakura, S Yokoi… - International journal of …, 2015 - Springer
Background The brain is a frequent site of metastases from non-small-cell lung cancer
(NSCLC). We analyzed the frequency of brain metastases (BMs) from NSCLC in the era of …
(NSCLC). We analyzed the frequency of brain metastases (BMs) from NSCLC in the era of …
Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: comparison between t790m …
A Hata, N Katakami, H Yoshioka, J Takeshita… - Cancer, 2013 - Wiley Online Library
BACKGROUND The secondary epidermal growth factor receptor (EGFR) mutation
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
Thr790Met (T790M) accounts for approximately half of acquired resistances to EGFR …
[HTML][HTML] Molecularly targeted therapies in non–small-cell lung cancer annual update 2014
D Morgensztern, MJ Campo, SE Dahlberg… - Journal of Thoracic …, 2015 - Elsevier
There have been significant advances in the understanding of the biology and treatment of
non–small-cell lung cancer (NSCLC) during the past few years. A number of molecularly …
non–small-cell lung cancer (NSCLC) during the past few years. A number of molecularly …
[HTML][HTML] The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively?
PH Patel, D Palma, F McDonald, AC Tree - Clinical Oncology, 2019 - Elsevier
Oligoprogressive disease is a relatively new clinical concept describing progression at only
a few sites of metastasis in patients with otherwise controlled widespread disease. In the era …
a few sites of metastasis in patients with otherwise controlled widespread disease. In the era …